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Abstract 
Background: The effects of insulin on cardiomyocytes, such as positive inotropic action and glucose uptake are well 
described. However, in vitro studies comparing long-acting insulin analogues with regard to cardiomyocyte signalling 
and function have not been systematically conducted.
Methods: Insulin receptor (IR) binding was assessed using membrane embedded and solubilised IR preparations. 
Insulin signalling was analysed in adult rat ventricular myocytes (ARVM) and HL-1 cardiac cells. Inotropic effects 
were examined in ARVM and the contribution of Akt to this effect was assessed by specific inhibition with triciribine. 
Furthermore, beating-rate in Cor.4U® human cardiomyocytes, glucose uptake in HL-1 cells, and prevention from H2O2 
induced caspase 3/7 activation in cardiac cells overexpressing the human insulin receptor (H9c2-E2) were analysed. 
One-way ANOVA was performed to determine significance between conditions.
Results: Insulin degludec showed significant lower IR affinity in membrane embedded IR preparations. In HL-1 
cardiomyocytes, stimulation with insulin degludec resulted in a lower Akt(Ser473) and Akt(Thr308) phosphorylation 
compared to insulin, insulin glargine and its active metabolite M1 after 5- and 10-min incubation. After 60-min treat-
ment, phosphorylation of Akt was comparable for all insulin analogues. Stimulation of glucose uptake in HL-1 cells 
was increased by 40–60 %, with a similar result for all analogues. Incubation of electrically paced ARVM resulted for all 
insulins in a significantly increased sarcomere shortening, contractility- and relaxation–velocity. This positive inotropic 
effect of all insulins was Akt dependent. Additionally, in Cor.4U® cardiomyocytes a 10–20 % increased beating-rate 
was detected for all insulins, with slower onset of action in cells treated with insulin degludec. H9c2-E2 cells chal-
lenged with H2O2 showed a fivefold increase in caspase 3/7 activation, which could be abrogated by all insulins used.
Conclusions: In conclusion, we compared for the first time the signalling and functional impact of the long-acting 
insulin analogues insulin glargine and insulin degludec in cardiomyocyte cell models. We demonstrated similar effi-
cacy under steady-state conditions relative to regular insulin in functional endpoint experiments. However, it remains 
to be shown how these results translate to the in vivo situation.
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Background
In addition to skeletal muscle, liver and adipose tis-
sue, the heart with 10,000–100,000 expressed insulin 
receptors (IRs) per cardiomyocyte [1] must be considered 
as an additional major organ affected by insulin (Ins). In 
cardiomyocytes, Ins modulates glucose transport, metab-
olism, protein synthesis, hypertrophy, contractility, beat-
ing-rate, and apoptosis [1–3].
Long-acting insulin analogues are designed to deliver 
a constant basal Ins supply throughout the day via the 
subcutaneous route resulting in improved fasting blood 
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glucose and overall glycaemic control while reducing the 
risk of hypoglycaemia [4–6]. Insulin glargine (IGla) has 
one amino acid exchange in the A-chain and two addi-
tional arginine residues at the B-chain, resulting in an 
altered isoelectric point that leads to local precipitation 
after subcutaneous injection [7, 8]. From this depot, IGla 
is slowly dissolved followed by immediate biotransfor-
mation into the active metabolite M1 (IGlaM1) [9, 10]. 
For insulin degludec (IDeg) it has been proposed that 
its protracted action results from slow dissolution of 
subcutaneous multi-hexamer assemblies [11]. However 
the structure of the side chain attached to this molecule 
(n-16 fatty acid) [11] suggests that the protraction mode 
may be similar to that of insulin detemir, which binds to 
human serum albumin (HSA) via its fatty acid side chain, 
thereby protracting its duration of action by providing a 
‘floating depot’ with the consequence of a reduced bio-
logical availability [12–14].
Besides the benefits of Ins analogue modification, 
modifying the Ins molecule may lead to an altered acti-
vation profile such as receptor signalling or pharmaco-
dynamics and pharmacokinetics. Recently the effects of 
Ins analogues on the cardiovascular system gained con-
siderable interest. So far, finalised clinical data is only 
available for IGla, whereas for IDeg the investigation is 
still ongoing. Results from the Outcome Reduction With 
Initial Glargine Intervention (ORIGIN) trial proved 
non-inferiority of IGla compared to standard care treat-
ment in regard to cardiovascular effects (Trial number 
NCT00069784) [15]. Just recently the interim analysis 
of the dedicated cardiovascular outcome trial for IDeg 
(DEVOTE) (Trial number NCT01959529), requested in 
2013 by the American Food and Drug Administration 
(FDA) [16] suggested non-inferiority to IGla, leading to 
approval of IDeg for the US market with a post market-
ing commitment to provide further non-inferiority data 
in major adverse cardiovascular events [17]. These clini-
cal trials were designed to compare systemic metabolic 
effects of the analogues in patients. However, strong evi-
dence for tissue-specific action of Ins exists [18] and to 
the best of our knowledge, there are no in vitro studies 
published which elucidate and compare the effect of dif-
ferent long-acting Ins analogues on cardiomyocyte cell 
models. Thus, data regarding the signalling and function 
of Ins analogues in cardiomyocyte cell models might 
shed light on potential differences of these drugs in rela-
tion to their cardiac action. Therefore, we compared the 
impact of IGla, IGlaM1, and IDeg to Ins in regard to 
signalling, contractility and anti-apoptotic potency in 
HL–1 cardiomyocytes, ARVM, H9c2-E2, and Cor.4U® 
cells. Our data show a very similar cardiomyocyte action 




The cardiac mouse cell line HL-1, a cell line derived from 
the AT-1 mouse atrial cardiomyocyte tumour lineage 
[19], was kindly provided by Dr. W.C. Claycomb (Loui-
siana State University, New Orleans, LA, USA). HL-1 
cells were cultivated in Claycomb medium containing 
10 % fetal calf serum (FCS), 100 µM norepinephrine and 
4  mM  l-glutamine (all from Sigma-Aldrich, Munich, 
Germany) on gelatine/fibronectin coated plates. H9c2 
cells (ATCC CRL-1446), stably transfected with the 
human IR in our laboratory [20] (H9c2-E2) were culti-
vated in DMEM, low glucose containing 10 % FCS, 1 % 
non–essential amino acids and 600 µg/ml G418 (all from 
Invitrogen, Carlsbad, CA, USA). Commercially avail-
able iPS-derived human cardiomyocytes (Cor.4U®) (Axi-
ogenesis, Cologne, Germany) were cultured in Cor.4U® 
Complete Medium containing 10  % FCS on fibronec-
tin–coated 96-well E-Plate (Acea Biosciences, San Diego, 
CA, USA). The medium was changed twice daily. All cells 
were incubated at 37  °C with 5  % CO2 in a humidified 
incubator.
Competition binding experiments on membrane 
embedded and solubilised insulin receptor preparations
Isolation of insulin receptor embedded plasma mem-
branes (M-IR) and competition binding experiments 
were performed as previously described [21]. Briefly, 
CHO-cells overexpressing the IR were collected and re-
suspended in ice-cold 2.25 STM buffer (2.25 M sucrose, 
5 mM Tris–HCl pH 7.4, 5 mM MgCl2, complete protease 
inhibitor) and disrupted using a Dounce homogenizer 
followed by sonication. The homogenate was overlaid 
with 0.8 STM buffer (0.8 M sucrose, 5 mM Tris–HCl pH 
7.4, 5 mM MgCl2, complete protease inhibitor) and ultra-
centrifuged for 90 min at 100,000g. Plasma membranes at 
the interface were collected and washed twice with phos-
phate buffered saline (PBS). The final pellet was re-sus-
pended in dilution buffer (50 mM Tric-HCl pH 7.4, 5 mM 
MgCl2, complete protease inhibitor) and again homog-
enised with a Dounce homogenizer. Competition binding 
experiments were performed in a binding buffer (50 mM 
Tris–HCl, 150 mM NaCl, 0.1 % BSA, complete protease 
inhibitor, adjusted to pH 7.8) in 96-well microplates. In 
each well 2  µg isolated membrane were incubated with 
0.25  mg wheat germ agglutinin polyvinyltoluene poly-
ethylenimine scintillation proximity assay (SPA) beads. 
Constant concentrations of [125I]-labelled human Ins 
(100 pM) and various concentrations of respective unla-
belled Ins (0.001–1000 nM) were added for 12 h at room 
temperature (23  °C). The radioactivity was measured at 
equilibrium in a microplate scintillation counter (Wallac 
Microbeta, Freiburg, Germany).
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Binding on a freshly solubilised IR preparation (S-IR) 
was performed as previously described [22] with some 
modifications. Aliquots of membranes were incubated 
at 4  °C for 30  min in a solubilisation buffer (20  mM 
HEPES–NaOH, 100  mM NaCl, 10  mM MgSO4, 1  % 
(w/v) n-Dodecyl-ß-d-maltoside (Sigma-Aldrich, Munich, 
Germany), adjusted to pH 7.8 and Complete TM Pro-
tease Inhibitor cocktail). Thereafter, ultra-centrifuga-
tion was performed at 100,000g for 30  min and 4  °C to 
remove non–solubilised debris. Protein concentration in 
the supernatant was adjusted to 0.15 mg/ml with binding 
buffer (100 mM HEPES–NaOH, 100 mM NaCl, 10 mM 
MgSO4, 0.025 % (v/v) Tween-20, adjusted to pH 7.8 and 
complete TM protease inhibitor cocktail). To strepta-
vidin SPA beads (5 mg in 1000 ml binding buffer), 50 µl 
of an anti-IR alpha-antibody 83-7 (Abcam, Cambridge, 
UK) was added. After incubation for 30 min, SPA beads 
were once washed and finally re-suspended in 500  µl 
binding buffer. A solution of solubilised receptor (1  ml, 
0.15 mg/ml) was added and incubated for further 60 min, 
before washing and resuspension in 1.5 ml. Subsequently, 
100 µl re-suspended IR-Antibody-SPA beads (containing 
10 µg total protein) were mixed with 50 µl [125I]-labelled 
insulin tracer (100  pM) and 50  µl non-radioactive Ins 
(0.001 – 1000 nM), incubated for 12 h at room tempera-
ture (23  °C) under shaking, centrifuged for 2  min and 
measured in the scintillation counter (Wallac Microbeta, 
Freiburg, Germany).
Effect of insulin and insulin analogues on contractility 
of primary adult rat ventricular cardiomyocytes
Adult rat ventricular cardiomyocytes (ARVM) were iso-
lated from wild-type Lewis rats  (Lew/Crl) as previously 
described [23]. ARVM were cultivated 3 h in Medium 199 
with Hanks’ balanced salts containing 5  mM creatin, 
2  mM carnitine and 5  mM  taurine supplemented with 
10 % FCS and 1 % insulin/transferrin/selene on laminin–
coated dishes (ibidi GmbH, Martinsried, Germany). Sub-
sequently, ARVM were cultivated over-night in DMEM/
F12 containing 33  µM biotin and 17  µM pantothenate 
(Invitrogen, Carlsbad, CA, USA). Prior to measurement, 
ARVM were pre-incubated for 5 min with 100 nM of Ins 
(porcine Ins, Cat. No.: I5523, Sigma-Aldrich, Munich, 
Germany), IGla, IGlaM1 or IDeg (provided by Sanofi-
Aventis, Frankfurt a.M., Germany) in modified Tyrodes 
solution: 125 mM NaCl; 1.2 mM KH2PO4; 2.6 mM KCl; 
1.2  mM MgSO4*7H2O; 1  mM CaCl2*2H2O; 10  mM 
Glucose; 10  mM HEPES; adjusted to pH =  7.4 prior to 
measurement. Furthermore, untreated ARVM or ARVM 
treated with 10  nM isoproterenol (Sigma-Aldrich, 
Munich, Germany) were immediately measured. ARVM 
were paced with bipolar pulses in a contractility and fluo-
rescence system (IonOptix, Milton, MA, USA) at 15  V, 
1 Hz, 0.5 ms, at 37 °C for up to 10 min and 10–14 con-
tractions of at least 10 rod–shaped ARVM per condi-
tion were recorded. Sarcomeric shortening, shortening 
rate and re-lengthening rate were calculated using the 
IonWizard software (IonOptix, Milton, MA, USA). To 
determine the role of Akt for the positive inotropic effect 
of Ins and the analogues, ARVM were pre-treated with 
10  µM of the specific Akt–inhibitor triciribine (Sigma-
Aldrich, Munich, Germany) for 30  min in contraction 
buffer. Afterwards, ARVM were treated as described 
above. After 30  min treatment with 10  µM triciribine, 
ARVM viability was assessed by incubating the cells with 
0.1 % trypan blue in PBS for 5 min. Microscopic pictures 
were taken randomly with at least 10 pictures per con-
dition. As a positive control 200  µM H2O2 was utilised. 
For each condition at least 400 cells were counted per 
experiment.
Immunoblotting
ARVM and HL-1 cells were treated as indicated and lysed 
in buffer containing 50 mM HEPES (pH 7.4) (PromoCell, 
Heidelberg, Germany), 1 % Triton X-100 (Sigma-Aldrich, 
Munich, Germany), PhosSTOP and CompleteTM pro-
tease inhibitor cocktail (Roche, Basel, Switzerland). After 
incubation for 2 h at 4 °C, the suspension was centrifuged 
at 10,000g for 15  min. 5  μg protein sample of the total 
cell lysate was separated by SDS/PAGE (10  % gel) and 
transferred to a polyvinylidene fluoride (PVDF) mem-
brane. Membranes were blocked in tris-buffered saline 
(TBS) containing 0.1 %  tween 20 and 5 % (w/v) non-fat 
dried skimmed milk powder and incubated overnight 
with anti-phospho Akt(Ser473) antibody, anti-phospho 
Akt(Thr308), anti-GAPDH antibody (all Cell Signalling 
Technology, Danvers, MA, USA) or anti-tubulin antibody 
(Abcam, Cambridge, UK). After washing, membranes 
were incubated with appropriate horseradish peroxidase-
coupled secondary antibody and processed for enhanced 
chemiluminescence (ECL) detection using Immobil-
ion horse radish peroxidase (HRP) substrate (Millipore, 
Darmstadt, Germany). Signals were visualised and evalu-
ated on a VersaDoc 4000 MP Bio-Rad Laboratories work 
station and analysed by Quantity One analysis software 
(version 4.6.7) (both Bio-Rad Laboratories, Hercules, CA, 
USA).
Impedance measurement in human Cor.4U® cells
Cor.4U® cardiomyocytes were seeded at a density of 
30,000 cells per well. From day 3 on the cells were cul-
tured in Iscove’s Basal Medium containing 1  %  Glu-
taMAX supplement (both Life Technologies, Carlsbad, 
CA, USA) and 2  µg/ml Ciprobay (Bayer, Leverkusen, 
Germany). Treatment with 500 nM of the designated Ins 
or analogue or 100 nM isoproterenol was started at day 4 
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after seeding. Impedance of each well was measured with 
the RTCA Cardio xCELLigence Analyser [24] (Acea Bio-
sciences, San Diego, CA, USA) during the whole experi-
ment. Beating-rate and cell index were analysed by RTCA 
cardio software (Acea Biosciences, San Diego, CA, USA).
Glucose uptake in HL‑1 cardiomyocytes
HL-1 cells were seeded at a density of 400,000 cells per 
well in a 12-well plate. Glucose uptake was measured 
in serum-starved HL-1 cells, either kept untreated or 
exposed for 60  min to 200  nM Ins and the analogues, 
respectively. Subsequently 0.12  mM  deoxy–d–glucose 
(Sigma-Aldrich, Munich, Germany) with 0.055  mCi 2–
deoxy–D–[14C]glucose (PerkinElmer, Waltham, MA, 
USA) was added to the cells. After 10 min incubation the 
uptake was terminated by repeated washing with ice cold 
PBS. Afterwards, the cardiomyocytes were lysed with lysis 
buffer containing 1  %  SDS and 200  mM  NaOH. Incor-
porated glucose was measured by scintillation counting 
of the cell lysates in a liquid scintillation counter (Beck-
man Coulter, Pasadena, CA, USA). Values were corrected 
for non-specific uptake as measured by incubation with 
L-[14C]glucose (PerkinElmer, Waltham, MA, USA).
Caspase 3/7 activity assay
To assess the anti-apoptotic effect of Ins and its ana-
logues, H9c2-E2 cells were seeded in a density of 5000 
cells per well of a 96-well plate. The next morning cells 
were treated with 100 nM of the respective Ins either in 
the presence or absence of 800 µM of H2O2 for 2 h. Cas-
pase 3/7 activity was then measured by the caspase-Glo® 
3/7 assay system (Promega, Madison, Wisconsin, USA) 
as described in the manual. After 2 h incubation period 
caspase 3/7 activity was analysed by measuring the lumi-
nescence in an Infinite 200 plate reader (Tecan, Männe-
dorf, Switzerland).
Statistical analysis
Results are expressed as mean values ± SEM of at least 
three independent experiments. For statistical analysis 
Graphpad Prism v5.00 (Graphpad Software, San Diego, 
CA, USA) was used. One-way ANOVA was performed 
to determine significance between conditions, with level 
of significance chosen at p < 0.05. In case of IC50 deter-
minations for binding, a non-parametric Kruskal–Wallis 
testing was performed, again with level of significance 
chosen at p < 0.05.
Results
Insulin degludec shows lower binding affinity and slower 
onset of insulin signalling
First we compared the binding affinities of Ins, IGlaM1 
and IDeg with a competitive binding assay using M-IR 
(Fig. 1a) and S-IR (Additional file 1: Figure S1). The anal-
ysis revealed an IC50 value of 0.83 ± 0.07 nmol/L for Ins 
in M-IR binding assays (Table 1). The IC50 of IGlaM1 and 
IDeg were 1.8- and 23.6-fold higher compared to Ins, 
reflecting a substantial lower binding affinity for IDeg. 
However, in S-IR binding assays we observed higher 
binding affinities for all tested insulins. The IC50 value for 
Ins was 0.58 ± 0.10 nmol/L (Additional file 2: Table S1). 
Under these conditions binding of IDeg improved with a 
5.4-fold higher IC50 compared to Ins. Next, to compare 
the activation of the Ins signalling cascade by Ins, IGla, 
IGlaM1 and IDeg, we assessed the Ser473 phosphoryla-
tion of Akt by western blot analysis in HL-1 cardiomyo-
cytes (Fig. 1b–d). The time-course revealed a significantly 
lower Akt(Ser473) phosphorylation level after 5 and 
10  min treatment with IDeg, compared to Ins and the 
other Ins analogues at 200  nM. After 60  min treatment 
IDeg showed a similar Akt(Ser473) phosphorylation level 
compared to Ins and IGlaM1; however, it was still signifi-
cantly lower compared to IGla (Fig. 1d). The same kinetic 
was observed for Akt(Thr308) phosphorylation (Addi-
tional file 3: Figure S2).
Positive inotropic effect of insulin and long‑acting insulin 
analogues
To confirm a full activation of Akt in ARVM under exper-
imental conditions, we first analysed the Akt (Ser473) and 
Akt (Thr308) activation after 10 min incubation with Ins 
and the different analogues. We observed a comparable 
Akt response under all conditions (Fig.  2a; Additional 
file  4: Figure S3). Next, we compared the positive ino-
tropic effect of the different Ins analogues to Ins in freshly 
isolated ARVM. ARVM pre-treated with 100  nM Ins, 
IGla, IGlaM1 and IDeg for 5  min, respectively showed 
a significant increase in sarcomeric shortening (~2.5-
fold), which describes the total sarcomeric shortening 
per sarcomere in µm (Fig.  2b). Departure- (~twofold) 
(Fig. 2c) and return velocity (~threefold) (Fig. 2d), which 
describes the shortening rate and re-lengthening rate of 
single sarcomeres in µm/s, are significantly increased 
compared to the control situation (Fig. 2). As can be seen 
from the data, an equipotent positive inotropic effect was 
observed for all analogues.
The positive inotropic effect of insulin and long‑acting 
insulin analogues is Akt dependent
To assess the role of Akt in the insulin-induced inotropic 
effect, we treated ARVM with the specific Akt-inhibitor 
triciribine. Triciribine in a concentration of 10  µM did 
not affect cell viability as determined by trypan blue stain-
ing (Additional file 5: Figure S4). After 30 min pre-incu-
bation with triciribine Ins signalling (Fig.  3a; Additional 
file 4: Figure S3) was completely abolished with all tested 
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insulins. In line with the signalling data, the positive ino-
tropic effect of Ins and the different insulin analogues was 
completely abolished at the level of all cardiac contrac-
tion parameters, such as sarcomeric shortening (Fig. 3b), 
departure velocity (Fig. 3c) and return velocity (Fig. 3d).
Both insulin glargine and insulin degludec increase the 
beating rate of human cardiomyocytes
To investigate long-term effects of insulin and its ana-
logues on the beating–rate of human iPSC-derived 
Fig. 1 Binding affinity and Akt signalling of long-acting insulin analogues. a Membrane embedded insulin receptor preparations were used to 
analyse binding of Ins, IGlaM1 and IDeg in a competition binding assay, as described in [21]. Percentage of binding is normalised to maximum 
binding of [125I]-labelled human insulin. Data represent mean values ± SEM, n = 4-5. b–d HL-1 cells were used to assess the onset of insulin action 
by treatment with 200 nM for 5 (b); 10 (c) or 60 min (d) with insulin or insulin analogues. Phosphorylation of Akt(Ser473) was assessed by Western 
blot analysis. Data are normalised to tubulin levels. Representative blots are shown. Data represent mean values ± SEM, n = 4–5, *p < 0.05 vs. basal, 
#p < 0.05 vs. IDeg. Regular insulin Ins, insulin glargine IGla, active metabolite of insulin glargine IGlaM1, insulin degludec IDeg
Table 1 Summary of competition binding assay using M-IR
Data represent mean ± SEM. All insulins were tested in at least four independent 
experiments on different days. Binding values within a single experiment were 
obtained in quadruplicates per insulin and averaged for each experiment
Ins Regular insulin; IGlaM1 active metabolite of glargine; IDeg insulin degludec
Insulin IR affinity IC50 (nmol/L) P value vs. Ins
Ins 0.83 ± 0.07 –
IGlaM1 2.15 ± 0.61 0.2350
IDeg 19.59 ± 1.10 <0.0001
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cardiomyocytes (Cor.4U®) we used an impedance-based 
measurement approach. To determine baseline values, 
beating–rate prior to substance application was ana-
lysed. In all measured conditions the mean beating-rate 
was around 30 beats per minute (bpm) (Fig. 4a). Since we 
did not observe any effects with 100  nM of the respec-
tive insulins, we used 500  nM for the treatment of the 
Cor.4U® cells. After substance application Ins, IGla and 
IGlaM1 reach their maximum beating-rate after 10 min, 
whereas IDeg reaches its maximum with a delay after 
20 min (Fig. 4b) and subsequently, the increased beating-
rate remained stable for up to 6  h (Fig.  4c). For better 
comparison of the increased beating-rate in each condi-
tion we calculated the area under the curve for the whole 
measurement (Fig. 4d). The analysis revealed a significant 
increase in the beating-rate for Ins, IGla, IGlaM1 and 
IDeg.
Both insulin glargine and insulin degludec increase 
glucose‑uptake to the same extent as regular insulin
Since glucose metabolism is important for cardiomyo-
cyte function, we compared the potency of Ins, IGla, 
IGlaM1 and IDeg to stimulate glucose uptake in HL–1 
cells. Glucose uptake was significantly increased after 
200  nM of IGla, IGlaM1 and IDeg treatment (between 
1.46- and 1.58-fold) and no difference between the insu-
lins has been detected (Fig. 5).
Anti‑apoptotic efficiency of insulin glargine and insulin 
degludec is comparable to regular insulin
Next we evaluated the anti-apoptotic potency of the long-
acting insulin analogues in the rat cardiomyocyte cell line 
H9c2 overexpressing the human IR (H9c2-E2). For this 
purpose, we treated the cells with a combination of either 
insulin or the different analogues in the presence of 
Fig. 2 Effect of insulin and insulin analogues on Akt signalling and cardiac contraction in ARVM. Adult rat ventricular cardiomyocytes (ARVM) were 
treated for 10 min with 100 nM insulin or insulin analogues to investigate the insulin signalling pathway in these cells (a). ARVM were isolated by 
enzymatic digestion, starved overnight and treated with 100 nM insulin or insulin analogues or 10 nM isoproterenol as positive control. ARVM were 
paced at 1 Hz, 15 V, 0.5 ms with the IonOptix Myopacer Cell Stimulator System to assess the sarcomeric shortening (b), departure velocity (c) and 
return velocity (d). In each condition at least 10 contractions of 10-14 cardiomyocytes were measured under steady-state conditions. Data represent 
mean values ± SEM, n = 4, *p < 0.05 vs. basal. Regular insulin Ins, isoproterenol iso, insulin glargine IGla, active metabolite of insulin glargine IGlaM1, 
insulin degludec IDeg
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H2O2, and subsequently measured caspase 3/7 activation. 
After exposure to H2O2 we found a significant induction 
of caspase 3/7 activity in H9c2-E2 cell (4.8-fold) (Fig. 6). 
However, the combination of Ins and H2O2 decreased 
caspase 3/7 activity up to 70.3 % compared to H2O2 treat-
ment alone, and was not significant anymore. A similar 
effect was observed for all tested insulin analogues.
Discussion
Treatment of diabetic patients with insulin analogues has 
been shown to provide a more efficient, reproducible, and 
convenient therapy than regular insulin. The analogues 
may vary from insulin with respect to metabolic potency, 
stability or onset, and duration of action that is achieved 
by either sequence or secondary structural modifications. 
These changes may lead to an altered functional profile, 
emphasizing the importance of examining all steps in the 
action of an insulin analog in vitro and in vivo. Regard-
ing the effects of insulin analogues in cardiomyocyte cell 
models no published data is available. Therefore, we com-
pared the long–acting insulin analogues IGla and IDeg in 
cardiac cell models. Using this in vitro setting, we could 
show the absence of any difference in functional cardiac 
endpoint measurements and insulin signalling between 
the long-acting insulin analogues IGla and IDeg under 
steady state conditions.
Since Akt is a major element of the insulin signalling 
pathway, we first analysed the activation of Akt in ARVM 
and HL-1 cells after treatment with the different insulin 
analogues. Although our results show a slower onset of 
Akt activation in HL-1 cells treated with IDeg for 5 and 
10 min compared to the other insulins (Fig. 1b, c), we did 
Fig. 3 Impact of Akt inhibition on insulin-induced cardiac contraction. Adult rat ventricular cardiomyocytes (ARVM) were analysed either without 
pre-treatment (blank bars) or pre-treated with 10 µM of the specific Akt-inhibitor triciribine (filled bars) for 30 min. Subsequently, ARVM were treated 
with either 100 nM insulin or insulin analogues for 10 min to investigate the insulin signalling pathway after triciribine treatment (a). Furthermore, 
ARVM were treated with 100 nM of insulin or insulin analogues or 10 nM isoproterenol and paced at 1 Hz, 15 V, 0.5 ms with the IonOptix Myopacer 
Cell Stimulator System to assess the sarcomeric shortening (b), departure velocity (c) and return velocity (d). In each condition at least 10 contrac-
tions of 10–14 cardiomyocytes were measured. Data represent mean values ± SEM, n = 3–5, *p < 0.05 vs. basal (treated). Regular insulin Ins, isopro-
terenol iso, active metabolite of insulin glargine IGlaM1, insulin degludec IDeg
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not observe a difference in Akt activation in HL-1 cells 
treated for 60  min and acutely treated ARVM (Fig.  1d 
and 2a). We speculate that a possible explanation for the 
slower onset of Akt phosphorylation in HL-1 cells might 
be the low binding affinity of IDeg towards the IR. In 
receptor binding studies using S-IR of both isoforms, the 
binding affinity for IDeg was found to be 13–15 % relative 
to human insulin [25]. The results from our indirect bind-
ing assays with the S-IR show a similar binding affinity of 
IDeg with  ~18.6  % relative to human insulin. However, 
it should be noted that S-IR displays a less complex con-
struct compared to M-IR. In these preparations the IR 
is surrounded by lipids and protein complexes. In M-IR 
preparations IDeg showed a binding affinity of ~4 % com-
pared to Ins and  ~13  % compared to IGlaM1. It could 
be possible that the fatty acid residue attached to IDeg 
interacts with other components of the membrane, and 
therefore leading to a reduced binding affinity towards 
the IR. The very low binding affinity of IDeg in M-IR 
(Fig. 1a) could be an explanation for the slower onset of 
action observed in HL-1 and Cor.4U® cells. The results 
obtained in M-IR preparations with Ins and IGlaM1 and 
IDeg in S-IR are comparable to previously published data 
[21, 25].
Insulin-mediated Akt activation in the myocardium 
triggers a variety of processes, like glucose uptake, modi-
fication of calcium signalling and anti-apoptotic effects 
[26]. Even though under physiological conditions the 
main energy source for the heart is fatty acids, about 
one third is derived from glucose [27] and with increas-
ing blood glucose and insulin level, glucose becomes the 
favoured substrate in the heart [2]. Therefore, we next 
analysed the ability of IGla and IDeg to stimulate glucose 
uptake under steady-state conditions in HL-1 cells, since 
we observed a full Akt activation with IDeg after 60 min. 
Under these conditions we observed no difference 
between IGla and IDeg in the insulin stimulated glucose 
uptake compared to Ins. We therefore conclude that IGla 
Fig. 4 Effect of insulin glargine and insulin degludec on the beating-rate of human iPSC-derived cardiomyocytes. Commercially available human 
iPSC-derived cardiomyocytes (Cor.4U®) were used to assess the long-term effect of insulins on the beating-rate (a–d). Experiments were performed 
at day 4 after seeding. Cells were treated with 500 nM of insulin or insulin analogues or 100 nM isoproterenol, respectively. The beating-rate was 
measured for 6 h. a Basal beating-rate prior to substance application. b Beating-rate of the first 30 min after substance application. c 0.5–6 h time 
course of beating-rate in Cor.4U® cells after substance application. d Area under the curve for the 6 h beating-rate measurement. Data represent 
mean values ± SEM, n = 4, *p < 0.05 vs. basal. Regular insulin Ins, isoproterenol iso, insulin glargine IGla, active metabolite of insulin glargine IGlaM1, 
insulin degludec IDeg
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and IDeg are equipotent in regulating cardiac glucose 
consumption, at least under steady-state conditions.
Another important aspect of insulin function in car-
diomyocytes is the positive inotropic effect which was 
already described in the 1920s by Visscher and Mül-
ler [28] and is due to an increased excitation–contrac-
tion coupling, which in turn is controlled by entry and 
release of Ca2+ from the sacroplasmatic reticulum (SR). 
Using insulin and the insulin analogues we observed a 
similar positive inotropic effect, as shown by compa-
rable increased sarcomeric shortening, departure- and 
return-velocity in ARVM. Furthermore, we could show 
that the positive inotropic effect in ARVM is completely 
Akt dependent. The Akt dependency of cardiomyo-
cyte contraction was shown previously by Graves et  al. 
in HL-1 cells, where inhibition of Akt activation leads 
to decreased total [Ca2+]i, intracellular Ca2+ transients 
and membrane ICa [29]. Furthermore, Reinartz et al. [30] 
recently showed that Akt1 and Akt2 knockdown affected 
phosphorylation of proteins involved in regulation of 
heart contraction as well as relaxation and regulation of 
heart rate. Additionally, proteins involved in Ca2+ release 
and re-entry into the SR are affected (e.g. CaMKII or 
phospholamban, a direct target of Akt) [30, 31], which 
could be a possible explanation for the complete abroga-
tion of the positive inotropic effect after Akt-inhibition. 
Insulin increases the beating–rate of cardiac muscle, but 
the underlying mechanism is controversially discussed 
in the literature. While some groups found evidence 
for insulin to directly increase the beating-rate in  vivo 
[32, 33], others claimed that insulin acts on the nerv-
ous system and thereby leads to beta-adrenergic stimu-
lation of the heart [34, 35]. In our in  vitro experiments 
with Cor.4U® cells we observed a slight but significant 
increase in beating-rate of Cor.4U® cardiomyocytes for 
up to 6 h. As observed in HL–1 signalling, we measured a 
slower onset of action with IDeg. However under steady 
state conditions no differences between the different 
analogues could be detected. Together with the results 
from the ARVM contraction experiments we conclude 
that the increase in beating–rate of cardiomyocytes is at 
least partly independent of nervous system activity and 
directly affected by insulin itself.
Furthermore, insulin is known to reduce the dam-
age of ischemia/reperfusion injury (IRI) in  vivo as well 
as in  vitro [36–39]. This damage is induced by mas-
sive production of reactive oxygen species (ROS) [40]. 
While diabetes per se is a risk factor for ischemic heart 
disease, the damage inflicted by IRI is even worse in dia-
betic patients [41]. Therefore, we aimed to mimic IRI in 
H9c2–E2 cardiomyocytes by challenging the cells with 
H2O2 with subsequent measurement of caspase 3/7 activ-
ity. To elucidate the potency of IGla and IDeg in preven-
tion of caspase 3/7 activation during ROS treatment, we 
treated part of the cells with a combination of H2O2 and 
the respective insulin. With our results we were able to 
reproduce the protective effect of Ins during IRI and fur-
thermore we were able to show that both, IGla and IDeg, 
have the same potency to prevent caspase 3/7 activation 
as Ins.
Fig. 5 2-deoxy-d-glucose uptake in HL-1 cells after insulin stimula-
tion with regular insulin and long-acting insulin analogues. HL-1 cells 
were used to assess the effect of insulin, insulin glargine, the active 
metabolite M1 and insulin degludec on 2-deoxy-d-glucose uptake. 
The cells were pre-treated with 200 nM of the indicated insulin for 
1 h. Subsequently, the cells were exposed to radioactive labelled mix 
containing 2–deoxy–d–glucose and 2–deoxy–d–[1–14C]glucose for 
10 min at 37 °C. Data represent mean values ± SEM, n = 4, *p < 0.05 
vs. basal. Regular insulin Ins, insulin glargine IGla, active metabolite of 
insulin glargine IGlaM1, insulin degludec IDeg
Fig. 6 Anti-apoptotic potency of long-acting insulin analogues 
in the presence of H2O2. H9c2 cardiomyocytes overexpressing the 
human insulin receptor (H9c2-E2 cells) were treated for 2 h with 100 
nM of insulin and insulin analogues in the presence or absence of 
800 µM H2O2 to evaluate the cardio protective effects of insulin and 
its analogues. Caspase 3/7 activity was measured using the promega 
caspase 3/7 Glo Assay. Each condition was performed in quadrupli-
cates. Data represent mean values ± SEM, n = 5–6, *p < 0.05 vs. basal. 
Regular insulin Ins, insulin glargine IGla, active metabolite of insulin 
glargine IGlaM1, insulin degludec IDeg
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Conclusion
In conclusion, the long-acting insulin analogues IGla and 
IDeg show no major differences in several cardiomyocyte 
in vitro models regarding insulin signalling, contractility 
parameters, beating–rate, glucose uptake, and protec-
tion from oxidative stress–induced caspase 3/7 activa-
tion under steady-state conditions. However, for IDeg we 
observed a slower onset of action in Akt phosphorylation 
in HL-1 cells as well as slower response to IDeg in human 
Cor.4U® cardiomyocytes. Additionally, we observed 
very low binding affinities of IDeg in M-IR preparations. 
Whether these effects translate to the complex in  vivo 
situation needs further evaluation.
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